Trials / Completed
CompletedNCT00674466
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy
A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Twice-a-week Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- ConjuChem · Industry
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on metformin monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 1.5 mg or 2.0 mg CJC-1134-PC | twice-a-week |
| DRUG | Placebo | twice-a-week |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-05-07
- Last updated
- 2017-06-02
- Results posted
- 2017-06-02
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00674466. Inclusion in this directory is not an endorsement.